Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins. The effects of AIM pharmacology have been documented in more than 200 scientific papers and are potentially relevant to a wide range of diseases.

Irving, US
Size (employees)
64 (est)
Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US

Key People at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has office in Irving
Irving, US

Reata Pharmaceuticals Metrics

Reata Pharmaceuticals Summary

Market capitalization

$607.8 m

Closing share price

Reata Pharmaceuticals's current market capitalization is $607.8 m.

Reata Pharmaceuticals Financials

Reata Pharmaceuticals's revenue is $49.9 m in FY, 2016
FY, 2016


$49.9 m

Net Income

($6.2 m)

Reata Pharmaceuticals Market Value History

Reata Pharmaceuticals Online Presence

Reata Pharmaceuticals Company Life

You may also be interested in